Freeline Therapeutics Holdings plc Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from 2018 to 2022

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Freeline Therapeutics Holdings plc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2018 to 2022.
  • Freeline Therapeutics Holdings plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending March 31, 2023 was $2.44M.
  • Freeline Therapeutics Holdings plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$102M, a 27.6% increase from 2021.
  • Freeline Therapeutics Holdings plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$140M, a 67% decline from 2020.
  • Freeline Therapeutics Holdings plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$84M, a 55.3% decline from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$102M +$38.7M +27.6% Jan 1, 2022 Dec 31, 2022 20-F 2023-04-04
2021 -$140M -$56.3M -67% Jan 1, 2021 Dec 31, 2021 20-F 2023-04-04
2020 -$84M -$29.9M -55.3% Jan 1, 2020 Dec 31, 2020 20-F 2023-04-04
2019 -$54.1M -$19.9M -58.5% Jan 1, 2019 Dec 31, 2019 20-F 2022-03-31
2018 -$34.1M Jan 1, 2018 Dec 31, 2018 20-F 2021-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.